Pegaspargase Rechallenge Following Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic… | ScholarDeck

Paper

Pegaspargase Rechallenge Following Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 16-001.

New research · Internal Medicine

Pediatric blood & cancer · 3w

StudyPediatric blood & cancer· Aug 2026

Pegaspargase Rechallenge Following Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 16-001.

Melissa A Burns, Yael Flamand, Julia Keating … Lynda M Vrooman

Read paper

Allergy & ImmunologyStudyTreatmentQ1IF 1.7

Pegaspargase rechallenge after grade 2 hypersensitivity succeeded in a minority of children with leukemia

Pegaspargase Rechallenge Following Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 16-001.

Melissa A Burns … Lynda M Vrooman

Pediatric blood & cancer · Aug 2026 · Q1 in General Medicine

Background

Hypersensitivity reactions with pegylated Escherichia coli-derived asparaginase formulations are frequent and can complicate delivery of intended therapy for patients with acute lymphoblastic leukemia (acute lymphoblastic leukemia).

Methods

On DFCI 16-001, which enrolled patients aged 1-21 years with newly diagnosed acute lymphoblastic leukemia, we piloted pegaspargase rechallenge after Grade 2 hypersensitivity reaction, including premedication and serum asparaginase activity (serum asparaginase activity) assessment.

Results

41.3%

the rechallenge dose succeeded in fewer than half of patients

“

Conclusion

This approach reduces the number of patients requiring switch to alternative asparaginase formulations, which have had limited availability and require frequent dosing.

Read paper